Dravet Syndrome Pipeline Assessment (2023 Updates) | in-Depth Insights Into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies

Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 12+ key pharma and biotech companies are working on 16+ pipeline drugs in the Dravet Syndrome therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Dravet Syndrome Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Dravet Syndrome Market

The Dravet Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Dravet Syndrome Pipeline Analysis

The report provides insights into: 

The report provides detailed insights into the emerging therapies for the treatment of Dravet Syndrome and the aggregate therapies developed by major pharma companies.

It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Dravet Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I) 

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Dravet Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 






Molecule Type

Products have been categorized under various Molecule types, such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody



Gene therapy

Mechanism of Action of the Emerging Pipeline Therapies

NAV1.1 voltage-gated sodium channel modulators

Vitamin K replacements

Cholesterol 24-hydroxylase inhibitors; NMDA receptor modulators

Serotonin 2C receptor agonists

NAV1.1 voltage-gated sodium channel modulators; RNA interference

GABA A receptor agonists

Serotonin receptor modulators 

TYK2 kinase inhibitors

Learn How the Ongoing Clinical & Commercial Activities will Affect the Dravet Syndrome Therapeutic Segment @


Dravet Syndrome Therapeutics Landscape

Several major pharma and biotech companies are developing therapies for Dravet Syndrome. Currently, Takeda is leading the therapeutics market with its Dravet Syndrome drug candidates in the most advanced stage of clinical development.

The Leading Players in the Dravet Syndrome Therapeutics Market Include:



Encoded Therapeutics

Epygenix Therapeutics

GW Pharmaceuticals

Longboard Pharmaceuticals

Ovid Therapeutics

PTC Therapeutics

Stoke Therapeutics


Virpax Pharmaceuticals


And Many Others

Dravet Syndrome Emerging and Marketed Drugs Covered in the Report Include:

EPX-100: Epygenix Therapeutics

STK-001: Stoke Therapeutics

LP352: Longboard Pharmaceuticals

BMB 101: Bright Minds Biosciences

NT102: Neuroene Therapeutics

STK 001: Stoke Therapeutics

Diazepam : XERIS Pharmaceuticals

Lorcaserin: Eisai Inc

Soticlestat: Takeda

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Dravet Syndrome Current Treatment Patterns

4. Dravet Syndrome – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Dravet Syndrome Late Stage Products (Phase-III)

7. Dravet Syndrome Mid-Stage Products (Phase-II)

8. Dravet Syndrome Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Dravet Syndrome Discontinued Products

13. Dravet Syndrome Product Profiles

14. Key Companies in the Dravet Syndrome Market

15. Key Products in the Dravet Syndrome Therapeutics Segment

16. Dormant and Discontinued Products

17. Dravet Syndrome Unmet Needs

18. Dravet Syndrome Future Perspectives

19. Dravet Syndrome Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Explore the Key Offerings of the Report



Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

Generated by Feedzy
%d bloggers like this: